Canaccord Genuity upgraded shares of Endo International (NASDAQ:ENDP) (TSE:ENL) from a hold rating to a buy rating in a research note issued to investors on Friday morning, MarketBeat Ratings reports. The brokerage currently has $20.00 target price on the stock, up from their prior target price of $16.00.
Several other equities research analysts have also recently commented on the company. Cowen reaffirmed a hold rating and set a $9.00 price objective on shares of Endo International in a research report on Friday. ValuEngine cut Endo International from a hold rating to a sell rating in a research report on Thursday. Cantor Fitzgerald increased their price objective on Endo International from $12.00 to $18.00 and gave the company a neutral rating in a research report on Friday, October 19th. BidaskClub raised Endo International from a buy rating to a strong-buy rating in a research report on Tuesday, October 2nd. Finally, Zacks Investment Research raised Endo International from a hold rating to a buy rating and set a $18.00 price objective on the stock in a research report on Monday, September 24th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. The company presently has a consensus rating of Hold and an average price target of $14.97.
Shares of NASDAQ ENDP traded up $0.30 during trading on Friday, reaching $13.49. The company had a trading volume of 6,440,068 shares, compared to its average volume of 4,723,015. Endo International has a 12-month low of $5.27 and a 12-month high of $18.50. The stock has a market cap of $3.59 billion, a P/E ratio of 3.51, a P/E/G ratio of 1.54 and a beta of 0.65.
Endo International (NASDAQ:ENDP) (TSE:ENL) last released its earnings results on Thursday, November 8th. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.12. Endo International had a positive return on equity of 237.45% and a negative net margin of 34.72%. The firm had revenue of $745.00 million for the quarter, compared to analysts’ expectations of $694.93 million. During the same period in the prior year, the firm posted $0.91 earnings per share. The company’s quarterly revenue was down 5.3% on a year-over-year basis. As a group, equities research analysts expect that Endo International will post 2.68 earnings per share for the current year.
In other Endo International news, Director Roger H. Kimmel sold 26,074 shares of the stock in a transaction dated Tuesday, August 14th. The stock was sold at an average price of $15.90, for a total value of $414,576.60. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 0.80% of the stock is currently owned by corporate insiders.
A number of hedge funds have recently bought and sold shares of ENDP. Xact Kapitalforvaltning AB lifted its holdings in Endo International by 44.5% in the first quarter. Xact Kapitalforvaltning AB now owns 29,215 shares of the company’s stock valued at $174,000 after acquiring an additional 9,000 shares during the period. James Investment Research Inc. raised its stake in shares of Endo International by 594.9% in the third quarter. James Investment Research Inc. now owns 10,945 shares of the company’s stock worth $184,000 after buying an additional 9,370 shares during the period. Harvest Fund Management Co. Ltd bought a new position in shares of Endo International in the third quarter worth about $223,000. Cim Investment Mangement Inc. bought a new position in shares of Endo International in the third quarter worth about $262,000. Finally, First Hawaiian Bank bought a new position in shares of Endo International in the third quarter worth about $358,000. 98.43% of the stock is currently owned by institutional investors.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Featured Article: Return on Equity (ROE)
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.